Publications by authors named "M de Moor"
Article Synopsis
- A study investigated the effectiveness of empagliflozin, a sodium-glucose cotransporter 2 inhibitor, in preventing kidney stones in nondiabetic adults with a history of calcium or uric acid stones.
- The trial involved 53 participants who were given either empagliflozin or a placebo in a crossover design, focusing on changes in urine supersaturation ratios relevant to stone recurrence.
- Results showed significant reductions in urine supersaturation ratios for calcium phosphate in calcium stone formers and uric acid in uric acid stone formers, indicating that empagliflozin may help prevent certain types of kidney stones without serious side effects.
Article Synopsis
- The study investigates how the surrounding DNA sequence affects the repair of double-stranded breaks caused by CRISPR/Cas9, using various genetically modified mouse embryonic stem cell lines.
- Researchers analyzed over 236,000 mutation outcomes from 2800 synthetic DNA sequences, discovering specific roles of DNA repair proteins like Prkdc and Polm in generating small insertions and deletions.
- They developed predictive models for these mutational outcomes based on their findings, enhancing the understanding of DNA repair mechanisms and enabling more accurate control of CRISPR-induced mutations.
Minimizing restrictive measures is an important lever to promote self-determination for people with intellectual disabilities. This study assesses the efficacy of the Multidisciplinary Expertise Team (MDET) program in reducing such measures within Dutch sheltered care homes for people with intellectual disabilities. A clustered randomized trial encompassed 30 residential units, reporting 428 measures on 107 residents through an organization-wide registration system.
View Article and Find Full Text PDFBackground: Ischemia-reperfusion injury (IRI) inevitably occurs during kidney transplantation and extended ischemia is associated with delayed graft function and poor outcomes. Remote ischemic preconditioning (RIPC) is a simple, noninvasive procedure aimed at reducing IRI and improving graft function. Experimental studies have implicated the kynurenine pathway as a protective mechanism behind RIPC.
View Article and Find Full Text PDFArticle Synopsis
- There is uncertainty around the use of apixaban in patients undergoing hemodialysis due to inconsistent study results and conflicting recommendations from health authorities, highlighting the need for further investigation into appropriate dosing.
- A study was conducted analyzing pre-dialysis apixaban levels in 24 patients with different dosing regimens, finding that higher drug levels were associated with twice daily dosing compared to once daily, and demonstrating that some patients had undetectable levels.
- The analysis also revealed that patients who experienced bleeding events had significantly higher drug levels and a majority of these patients were on concomitant antiplatelet therapy, suggesting that drug monitoring could enhance patient safety in this population.